Acrivon Therapeutics, Inc.
ACRV
$2.06
-$0.04-1.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.96M | -19.04M | -18.99M | -18.23M | -21.01M |
| Total Depreciation and Amortization | 405.00K | 383.00K | 361.00K | 349.00K | 335.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.55M | 2.62M | 3.49M | 4.14M | 4.01M |
| Change in Net Operating Assets | 146.00K | -4.49M | -99.00K | 1.47M | 52.00K |
| Cash from Operations | -14.86M | -20.54M | -15.24M | -12.28M | -16.61M |
| Capital Expenditure | -87.00K | -14.00K | -219.00K | -899.00K | -493.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.03M | 13.14M | 21.74M | 6.81M | 19.94M |
| Cash from Investing | 14.95M | 13.13M | 21.52M | 5.91M | 19.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.31M | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Stock | -34.00K | -33.00K | -192.00K | -117.00K | -97.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.00K | -- | -- | -- | -- |
| Cash from Financing | 7.27M | -33.00K | -192.00K | -117.00K | -97.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.35M | -7.44M | 6.10M | -6.49M | 2.74M |